Skip to main content

Department of Cell and Developmental Biology

Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers.

AUTHORS

Song W , Hwang Y , Youngblood VM , Cook RS , Balko JM , Chen J , Brantley-Sieders DM , . Oncogene. 2017 6 5; ().

ABSTRACT

Basal-like/triple-negative breast cancers (TNBCs) are among the most aggressive forms of breast cancer, and disproportionally affects young premenopausal women and women of African descent. Patients with TNBC suffer a poor prognosis due in part to a lack of molecularly targeted therapies, which represents a critical barrier for effective treatment. Here, we identify EphA2 receptor tyrosine kinase as a clinically relevant target for TNBC. EphA2 expression is enriched in the basal-like molecular subtype in human breast cancers. Loss of EphA2 function in both human and genetically engineered mouse models of TNBC reduced tumor growth in culture and in vivo. Mechanistically, targeting EphA2 impaired cell cycle progression through S-phase via downregulation of c-Myc and stabilization of the cyclin-dependent kinase inhibitor p27/KIP1. A small molecule kinase inhibitor of EphA2 effectively suppressed tumor cell growth in vivo, including TNBC patient-derived xenografts. Thus, our data identify EphA2 as a novel molecular target for TNBC.Oncogene advance online publication, 5 June 2017; doi:10.1038/onc.2017.170.

Tags:

VIEW MORE EVENTS >